Clinical MR imaging in Parkinson's disease: How useful is the swallow tail sign?


Journal

Brain and behavior
ISSN: 2162-3279
Titre abrégé: Brain Behav
Pays: United States
ID NLM: 101570837

Informations de publication

Date de publication:
07 2021
Historique:
revised: 01 04 2021
received: 15 02 2021
accepted: 11 05 2021
pubmed: 26 5 2021
medline: 12 8 2021
entrez: 25 5 2021
Statut: ppublish

Résumé

With conventional MRI, no Parkinson's disease (PD)-specific abnormalities can be detected. However, there is a critical need for accompanying neuroimaging markers to guide the diagnosis. With high-resolution susceptibility-weighted MRI (SWI) sequences, the imaging of nigrosome-1 (N1) is possible. The so-called swallow tail sign (STS) has been proposed as a suitable neuroimaging marker for the diagnosis of PD. To investigate whether the absence of the STS can be applied for distinguishing PD patients from healthy controls (HCs). SWI images of 44 PD patients and 50 age- and gender-matched HCs were investigated using a 3T MRI scanner. Two trained neuroradiologists blind-rated the images and evaluated whether the STS was absent (1) on one side or (2) both sides of the participant's midbrain. Our results confirmed good interrater reliability comparable to previously published studies. However, we did not identify any group differences between PD patients and HCs. Measures of diagnostic values revealed overall poor diagnostic performance. Even though previously stated, our study does not confirm the potential use of the STS as a supportive neuroimaging marker for PD in a clinical setting. In conclusion, there is a critical need for improvements in N1-targeted MRI sequences and the development of advanced segmentation algorithms.

Sections du résumé

BACKGROUND
With conventional MRI, no Parkinson's disease (PD)-specific abnormalities can be detected. However, there is a critical need for accompanying neuroimaging markers to guide the diagnosis. With high-resolution susceptibility-weighted MRI (SWI) sequences, the imaging of nigrosome-1 (N1) is possible. The so-called swallow tail sign (STS) has been proposed as a suitable neuroimaging marker for the diagnosis of PD.
OBJECTIVES
To investigate whether the absence of the STS can be applied for distinguishing PD patients from healthy controls (HCs).
METHODS
SWI images of 44 PD patients and 50 age- and gender-matched HCs were investigated using a 3T MRI scanner. Two trained neuroradiologists blind-rated the images and evaluated whether the STS was absent (1) on one side or (2) both sides of the participant's midbrain.
RESULTS
Our results confirmed good interrater reliability comparable to previously published studies. However, we did not identify any group differences between PD patients and HCs. Measures of diagnostic values revealed overall poor diagnostic performance.
CONCLUSIONS
Even though previously stated, our study does not confirm the potential use of the STS as a supportive neuroimaging marker for PD in a clinical setting. In conclusion, there is a critical need for improvements in N1-targeted MRI sequences and the development of advanced segmentation algorithms.

Identifiants

pubmed: 34032020
doi: 10.1002/brb3.2202
pmc: PMC8323030
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e02202

Subventions

Organisme : Deutsche Forschungsgemeinschaft
ID : BR4328.2-1
Organisme : Deutsche Forschungsgemeinschaft
ID : DFG-GEPRIS 413535489
Organisme : Deutsche Forschungsgemeinschaft
ID : GRK1957
Organisme : Deutsche Parkinsongesellschaft
Organisme : Parkinson's Foundation

Informations de copyright

© 2021 The Authors. Brain and Behavior published by Wiley Periodicals LLC.

Références

Clin Imaging. 2017 Jul - Aug;44:66-69
pubmed: 28460362
AJNR Am J Neuroradiol. 2017 Sep;38(9):1737-1741
pubmed: 28705819
Mov Disord. 2017 Apr;32(4):619-623
pubmed: 28151553
Pol J Radiol. 2016 Aug 03;81:363-9
pubmed: 27559425
BMC Neurol. 2017 Oct 26;17(1):194
pubmed: 29073886
Parkinsonism Relat Disord. 2012 Mar;18(3):225-9
pubmed: 21975260
Prog Nucl Magn Reson Spectrosc. 2018 Dec;109:1-50
pubmed: 30527132
Radiology. 2016 Jun;279(3):849-58
pubmed: 26690908
J Alzheimers Dis. 2019;67(1):61-65
pubmed: 30475767
Biometrics. 1977 Mar;33(1):159-74
pubmed: 843571
PLoS One. 2014 Apr 07;9(4):e93814
pubmed: 24710392
J Neuroimaging. 2019 Jan;29(1):65-69
pubmed: 30407679
Mov Disord. 2015 Oct;30(12):1591-601
pubmed: 26474316
Brain Behav. 2021 Jul;11(7):e02202
pubmed: 34032020
Mov Disord. 2016 May;31(5):684-92
pubmed: 26990970
PLoS One. 2020 Apr 2;15(4):e0231010
pubmed: 32240236

Auteurs

Jannik Prasuhn (J)

Institute of Neurogenetics, University of Lübeck, Lübeck, Germany.
Department of Neurology, University Medical Center Schleswig-Holstein, Lübeck, Germany.
Center for Brain, Behavior, and Metabolism, University of Lübeck, Lübeck, Germany.

Alexander Neumann (A)

Department of Neuroradiology, University Medical Center Schleswig-Holstein, Lübeck, Germany.

Robert Strautz (R)

Institute of Neurogenetics, University of Lübeck, Lübeck, Germany.
Department of Neurology, University Medical Center Schleswig-Holstein, Lübeck, Germany.
Department of Psychiatry and Psychotherapy, University Medical Center Schleswig-Holstein, Lübeck, Germany.

Shalida Dreischmeier (S)

Institute of Neurogenetics, University of Lübeck, Lübeck, Germany.
Department of Neurology, University Medical Center Schleswig-Holstein, Lübeck, Germany.

Felicitas Lemmer (F)

Institute of Neurogenetics, University of Lübeck, Lübeck, Germany.
Department of Neurology, University Medical Center Schleswig-Holstein, Lübeck, Germany.

Henrike Hanssen (H)

Institute of Neurogenetics, University of Lübeck, Lübeck, Germany.
Department of Neurology, University Medical Center Schleswig-Holstein, Lübeck, Germany.
Center for Brain, Behavior, and Metabolism, University of Lübeck, Lübeck, Germany.

Marcus Heldmann (M)

Department of Neurology, University Medical Center Schleswig-Holstein, Lübeck, Germany.
Center for Brain, Behavior, and Metabolism, University of Lübeck, Lübeck, Germany.
Institute of Psychology II, University Medical Center Schleswig-Holstein, Lübeck, Germany.

Peter Schramm (P)

Department of Neuroradiology, University Medical Center Schleswig-Holstein, Lübeck, Germany.

Norbert Brüggemann (N)

Institute of Neurogenetics, University of Lübeck, Lübeck, Germany.
Department of Neurology, University Medical Center Schleswig-Holstein, Lübeck, Germany.
Center for Brain, Behavior, and Metabolism, University of Lübeck, Lübeck, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH